Shanghai Henlius Biotech And Organon Announced That The Phase 3 Comparative Trial For The Investigational Perjeta (Pertuzumab) Biosimilar HLX11 Met The Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Shanghai Henlius Biotech and Organon announced that their Phase 3 trial for the Perjeta biosimilar HLX11 met its primary endpoint. Organon holds global commercialization rights for HLX11, excluding China.
September 30, 2024 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Organon, holding global commercialization rights for HLX11, announced successful Phase 3 trial results for the Perjeta biosimilar, potentially boosting its market position in the biosimilar space.
The successful Phase 3 trial of HLX11, for which Organon holds global commercialization rights, is likely to enhance Organon's position in the biosimilar market. This could lead to increased investor confidence and a positive short-term impact on Organon's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80